What is the scope of this report?

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry. Read More

Does this report estimates the current market size?

The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027. Read More

Does the report provides Market Size in terms of – Value (US$ Mn) and Volume (Thousands Units) - of the market?

The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units). Read More

Which segments covered in this report?

Market is segmented by Types, Applications, Technology, End-use Industries, and Regions. Read More

What are the key factors covered in this report?

The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions. Read More

Does this report offer customization?

Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs. Read More

Global Conjugate Vaccines Market (2019 - 2027)

Report Code : 262586
Industry : Healthcare and Pharmaceuticals
Published On : Dec 2019
Pages : 100
Publisher : Netscribes
Format:

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Request Sample

The market for conjugate vaccines is expected to increase, owing to global awareness about the benefits of vaccination for the prevention of certain life-threatening diseases, growing initiatives for production of low-cost vaccines, and widespread routine vaccination programmes in emerging economies. The market will witness a steady growth, expanding at a compound annual growth rate (CAGR) of 11.7% during 2017-2022, to reach approximately USD 87.7 Bn by 2022.
Disease indication segment insights:
Pneumococcal conjugate vaccine (PCV) held the largest market share (24.66%) in 2017 owing to the widespread nature of pneumococcal disease. Also, the leading vaccine-preventable cause of death among children around the world is the pneumococcal disease. Global initiatives were undertaken to speed up the introduction of pneumococcal vaccinations in low-income countries through partnerships among countries, donors, academia, international organizations, and industries. Close on its heels, the diphtheria and tetanus toxoids and pertussis (DTP) conjugate vaccine occupied a share of 23% in 2017. The higher prevalence of respiratory diseases such as whooping cough, among both children and adults, have led to the increased adoption of DTP conjugate vaccines. Haemophilus influenzae type b (Hib) conjugate vaccines are expected to grow at the fastest rate during 2017-2022.
End user segment insights:
The adult segment registered higher market share than the paediatric segment because of an increase in awareness on conjugate vaccines for adults, over the years. Still, the penetration level for adult conjugate vaccines is comparatively lower, with the lowest being for PCVs. Hence, the growth potential is very high. The paediatric vaccines, on the other hand is a stable market and depends highly on the birth rates in each region. The vaccination programmes, especially taken up by global organizations such as the United Nations Educational, Scientific and Cultural Organization (UNESCO), have been successful in eradicating many such vaccine-preventable diseases.
Regional insights:
Asia-Pacific is the largest market for conjugate vaccines, which held a share of 42%, in 2017. The primary indicators of the potential for the vaccine market is the geriatric population in the region, especially in countries such as India and China. In turn, this has, encouraged market participants to increase spending on research and development (R&D) and distribution facilities in the these countries. North America is the second biggest market for conjugate vaccines, owing to the region's widespread immunization programmes. The Middle East and Africa, and Latin America regions lack proper infrastructure and awareness of vaccine-preventable diseases, which are hindering market growth.

Companies covered:
1. GlaxoSmithKline
2. Pfizer Inc.
3. Merck & Co.
4. Novartis
5. Sanofi Pasteur
6. CSL Limited
7. Bharat Biotech International
8. Biological E Limited
9. Serum Institute of India

Customizations available
With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com, or connect with us here.

Chapter 1. Executive summary


1.1. Market scope and segmentation

1.2. Key questions answered 

1.3. Executive summary


Chapter 2. Global conjugate vaccine market - overview


2.1. Market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), geography-wise market revenue (USD Bn), and market attractiveness analysis

2.2. Market drivers

2.3. Market trends

2.4. Market challenges

2.5. Value chain analysis 

2.6. Porter's five forces analysis 

2.7. Segmentation based on disease indication (pneumococcal conugate vaccine (PCV), haemophilus influenzae type B (Hib) conjugate vaccine, diptheria, tetanus toxoids and pertussis (DTP) conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

2.8. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations


Chapter 3. North America conjugate vaccine market


3.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

3.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

3.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations


Chapter 4. Europe conjugate vaccine market


4.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

4.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

4.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations


Chapter 5. Asia-Pacific conjugate vaccine market 


5.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

5.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

5.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations


Chapter 6. Latin America conjugate vaccine market 


6.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

6.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

6.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations


Chapter 7. The Middle East and Africa conjugate vaccine market 


7.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

7.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

7.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations


Chapter 8. Competitive landscape


8.1. GlaxoSmithKline

8.1.a. Company snapshot

8.1.b. Products/services

8.1.c. Major initiatives/highlights

8.1.d. Growth strategy

8.1.e. Geographical presence

8.1.f. Key numbers 

Note: Similar information areas will be covered for the remaining competitors:

8.2. Pfizer Inc.

8.3. Merck & Co.

8.4. Novartis

8.5. Sanofi Pasteur

8.6. CSL Limited

8.7. Bharat Biotech International

8.8. Biological E Limited

8.9. Serum Institute of India


Chapter 9. Conclusion

9.1. Future outlook


Appendix

1. List of tables

2. Research methodology

3. Assumptions

4. About Netscribes Inc.

RDC (Radionuclide Drug Conjugate) Services Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

Price : US$ 3,500	Date : Oct 2024
Category : Healthcare and Pharmaceuticals	Pages : 129

Hepatitis B Vaccines Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

Price : US$ 3,500	Date : May 2024
Category : Healthcare and Pharmaceuticals	Pages : 110

Synex Korea Healthcare Business Issue Report - Private Medical Insurance 2022

Price : US$ 1,000	Date : Dec 2022
Category : Healthcare and Pharmaceuticals	Pages : 118

Global Low Carbon Ammonia Market (2024 Edition): Analysis By Type (Green Ammonia, and Blue Ammonia), By Technology, By End-Use, By Region, By Country: Market Insights and Forecast (2022-2032)

Price : US$ 2,450	Date : Feb 2024
Category : Chemicals and Materials	Pages : 280

Vaccines Isothermal Boxes Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

Price : US$ 3,500	Date : Mar 2024
Category : Manufacturing and Construction	Pages : 110

Choose License Type

Happy To Assist You

We will be happy to help you find what you need. Please call us or write to us:

Email
sales@worldwidemarketreports.com
United States Of America

+1-415-871-0703
United Kingdom

+44-203-289-4040
Australia

+61-2-4786-0457
INDIA

+91-848-285-0837

Sales Support:

Global Conjugate Vaccines Market (2019 - 2027)

Impact Analysis of Covid-19

RDC (Radionuclide Drug Conjugate) Services Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

Hepatitis B Vaccines Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

Synex Korea Healthcare Business Issue Report - Private Medical Insurance 2022

Global Low Carbon Ammonia Market (2024 Edition): Analysis By Type (Green Ammonia, and Blue Ammonia), By Technology, By End-Use, By Region, By Country: Market Insights and Forecast (2022-2032)

Vaccines Isothermal Boxes Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

Choose License Type

Happy To Assist You

Email

United States Of America

United Kingdom

Australia

INDIA

Frequently Asked Questions

What does this report covers?

Does this report estimates the current market size?

Does the report provides Market Size in terms of – Value (US$ Mn) and Volume (Thousands Units)?

What are the key segments offered in this report?

Which market dynamics covered in this report?

Does this report offer customization?

Related Reports

RDC (Radionuclide Drug Conjugate) Services Market Size And Share Analysis - Growth Trends And...

Hepatitis B Vaccines Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)

Synex Korea Healthcare Business Issue Report - Private Medical Insurance 2022

Global Low Carbon Ammonia Market (2024 Edition): Analysis By Type (Green Ammonia, And Blue Am...

Vaccines Isothermal Boxes Market Size And Share Analysis - Growth Trends And Forecasts (2024-...

Trusted Clients

Contact us

Sales Office (U.S.):

Asia Pacific Intelligence Center (India):

Menu

Quick Links

Newsletter

Secure Payment By: